ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : -11 مورد

Glycerin and lidocaine: Drug information

Glycerin and lidocaine: Drug information
2025© UpToDate, Inc. and its affiliates and/or licensors. All Rights Reserved.
For additional information see "Glycerin and lidocaine: Patient drug information"

For abbreviations, symbols, and age group definitions show table
Brand Names: US
  • RectiCare [OTC]
Pharmacologic Category
  • Antihemorrhoidal Agent;
  • Local Anesthetic
Dosing: Adult
Anorectal disorders

Anorectal disorders: Topical: Apply to the affected area ≤6 times daily (morning, evening, and after each bowel movement).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Liver Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric
Anorectal disorders

Anorectal disorders: Children ≥12 years and Adolescents: Topical: Refer to adult dosing.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Adverse Reactions

Also see individual agents. No adverse reactions listed in the manufacturer's labeling.

Contraindications

OTC labeling: When used for self-medication, do not put into the rectum using fingers or any mechanical device or applicator.

Warnings/Precautions

Concerns related to adverse effects:

• Methemoglobinemia: Has been reported with local anesthetics; clinically significant methemoglobinemia requires immediate treatment along with discontinuation of the anesthetic and other oxidizing agents. Onset may be immediate or delayed (hours) after anesthetic exposure. Patients with G6PD deficiency, congenital or idiopathic methemoglobinemia, cardiac or pulmonary compromise, exposure to oxidizing agents or their metabolites, or infants <6 months of age are more susceptible and should be closely monitored for signs and symptoms of methemoglobinemia (eg, cyanosis, headache, rapid pulse, shortness of breath, lightheadedness, fatigue).

Other warnings/precautions:

• Self-medication (OTC use): When used for self-medication, discontinue use and notify health care provider if rectal bleeding occurs; an allergic reaction develops; or if condition worsens, does not improve within 7 days, the symptoms being treated do not subside, or if redness, irritation, swelling, pain, or other symptoms develop or increase.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Pad, External:

RectiCare: Glycerin 20% and lidocaine 5% (12 ea) [contains benzyl alcohol]

Generic Equivalent Available: US

No

Pricing: US

Pads (RectiCare External)

5-20% (per each): $1.06

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

Topical: For external use only.

Cream: Prior to applying, cleanse affected area with cleansing wipe; dry with a tissue or a soft cloth.

Wipes: Prior to using, when possible, cleanse affected area with mild soap and warm water; rinse thoroughly. Gently apply wipe to affected area by patting; discard wipe.

Administration: Pediatric

Topical: For external use only in rectal area. Prior to applying cream, cleanse affected area with cleansing wipe; dry with a tissue or a soft cloth.

Use: Labeled Indications

Anorectal disorders: Temporary relief of pain, soreness, burning, itching, and discomfort associated with hemorrhoids; temporarily relief of anorectal discomforts; temporarily protects irritated and inflamed perianal skin.

Metabolism/Transport Effects

Refer to individual components.

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the drug interactions program by clicking on the “Launch drug interactions program” link above.

Antiarrhythmic Agents (Class IB): Lidocaine (Topical) may increase adverse/toxic effects of Antiarrhythmic Agents (Class IB). Risk C: Monitor

Articaine: May increase adverse/toxic effects of Local Anesthetics. Risk C: Monitor

Cimetidine: May increase serum concentration of Lidocaine (Topical). Risk C: Monitor

Dapsone (Topical): May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Risk C: Monitor

Dichlorphenamide: Laxatives may increase hypokalemic effects of Dichlorphenamide. Risk C: Monitor

Local Anesthetics: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor

Methemoglobinemia Associated Agents: May increase adverse/toxic effects of Local Anesthetics. Specifically, the risk for methemoglobinemia may be increased. Risk C: Monitor

Nitric Oxide: May increase adverse/toxic effects of Methemoglobinemia Associated Agents. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Prilocaine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Prilocaine. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Management: Monitor for signs of methemoglobinemia when prilocaine is used in combination with other agents associated with development of methemoglobinemia. Avoid use of these agents with prilocaine/lidocaine cream in infants less than 12 months of age. Risk C: Monitor

Primaquine: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Primaquine. Specifically, the risk for methemoglobinemia may be increased. Management: Avoid concomitant use of primaquine and other drugs that are associated with methemoglobinemia when possible. If combined, monitor methemoglobin levels closely. Risk D: Consider Therapy Modification

ROPivacaine: May increase adverse/toxic effects of Local Anesthetics. Risk C: Monitor

Sodium Nitrite: Methemoglobinemia Associated Agents may increase adverse/toxic effects of Sodium Nitrite. Combinations of these agents may increase the likelihood of significant methemoglobinemia. Risk C: Monitor

Pregnancy Considerations

Refer to individual monographs.

Breastfeeding Considerations

Refer to individual monographs.

Mechanism of Action

Glycerin: Acts as a skin protectant or lubricant.

Lidocaine: Blocks both the initiation and conduction of nerve impulses by decreasing the neuronal membrane's permeability to sodium ions, which results in inhibition of depolarization with resultant blockade of conduction.

Pharmacokinetics (Adult Data Unless Noted)

See individual agents.

  1. Preparation H (glycerin/lidocaine) [prescribing information]. Madison, NJ: Pfizer; January 2017.
  2. RectiCare Medicated Anorectal Wipes (glycerin and lidocaine) [prescribing information]. Detroit, MI: Ferndale Healthcare; May 2015.
Topic 114510 Version 74.0